全文获取类型
收费全文 | 833篇 |
免费 | 48篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 41篇 |
妇产科学 | 7篇 |
基础医学 | 46篇 |
口腔科学 | 13篇 |
临床医学 | 69篇 |
内科学 | 116篇 |
皮肤病学 | 5篇 |
神经病学 | 6篇 |
特种医学 | 140篇 |
外科学 | 98篇 |
综合类 | 10篇 |
预防医学 | 27篇 |
眼科学 | 57篇 |
药学 | 38篇 |
中国医学 | 1篇 |
肿瘤学 | 209篇 |
出版年
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 19篇 |
2017年 | 16篇 |
2016年 | 10篇 |
2015年 | 16篇 |
2014年 | 30篇 |
2013年 | 24篇 |
2012年 | 19篇 |
2011年 | 21篇 |
2010年 | 19篇 |
2009年 | 27篇 |
2008年 | 23篇 |
2007年 | 25篇 |
2006年 | 26篇 |
2005年 | 27篇 |
2004年 | 40篇 |
2003年 | 33篇 |
2002年 | 29篇 |
2001年 | 40篇 |
2000年 | 22篇 |
1999年 | 27篇 |
1998年 | 20篇 |
1997年 | 34篇 |
1996年 | 30篇 |
1995年 | 19篇 |
1994年 | 28篇 |
1993年 | 19篇 |
1992年 | 25篇 |
1991年 | 31篇 |
1990年 | 17篇 |
1989年 | 18篇 |
1988年 | 19篇 |
1987年 | 20篇 |
1986年 | 17篇 |
1985年 | 24篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 11篇 |
1981年 | 6篇 |
1980年 | 9篇 |
1976年 | 5篇 |
1967年 | 1篇 |
排序方式: 共有883条查询结果,搜索用时 0 毫秒
11.
Comprehensive mutational scanning of the p53 coding region by two- dimensional gene scanning 总被引:2,自引:0,他引:2
A comprehensive mutational scanning test for the p53 coding region based on
multiplex PCR and two-dimensional DNA electrophoresis was designed and
evaluated. In a 2-step multiplex PCR, the p53 coding region (exons 2-11)
was amplified as a single 8646-bp fragment by long- distance PCR in step
one. This fragment served as a template for the subsequent co-amplification
of the individual exons in two multiplex groups in step two. The multiplex
products were then separated, first on the basis of size in non-denaturant
polyacrylamide gels and then on the basis of sequence by denaturing
gradient gel electrophoresis (DGGE). Primers for optimal PCR, melting
behavior and 2-D gel distribution were designed using a recently developed
computer program. The resulting two-dimensional gene scanning (TDGS) test
was evaluated by screening, in a blinded fashion, 29 coded DNA samples from
Li- Fraumeni syndrome patients with previously identified germline
mutations. All mutations were correctly detected. This assay provides an
accurate, cost-effective and non-radioactive method for simultaneous
mutational scanning of all p53 coding exons.
相似文献
12.
C Manegold J Symanowski U Gatzemeier M Reck J von Pawel C Kortsik K Nackaerts P Lianes N J Vogelzang 《Annals of oncology》2005,16(6):923-927
BACKGROUND: A phase III trial in patients with malignant pleural mesothelioma demonstrated a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin. Because post-study chemotherapy (PSC) may have influenced the outcome of the trial, we examined its use and association with survival. PATIENTS AND METHODS: Eighty-four patients from the pemetrexed plus cisplatin arm and 105 patients from the single-agent cisplatin arm received PSC. Kaplan-Meier survival estimates were compared by treatment groups, and by PSC and non-PSC subgroups. RESULTS: The percentage of patients receiving PSC was imbalanced between the treatment arms. Fewer pemetrexed plus cisplatin treated patients received PSC (37.2% versus 47.3%). A multiple regression analysis performed in this trial showed that PSC had a statistically significant correlation with prolonged survival (P <0.01), adjusting for baseline prognostic factors and treatment intervention. The adjusted hazard ratio for PSC over non-PSC subgroups was 0.56 (confidence interval 0.44-0.72). CONCLUSIONS: PSC in malignant pleural mesothelioma was significantly associated with prolonged survival. It is not known whether the reduced risk of death was associated with PSC or whether patients who had prolonged survival tended to receive more PSC. The pemetrexed plus cisplatin treatment group had a statistically significant survival advantage even though fewer patients from that arm of the trial received PSC. The potentially beneficial role of PSC should be assessed in prospective trials. 相似文献
13.
Nicholas J. Vogelzang Sumanta K. Pal William M. Reichmann Nanxin Li Chelsey Yang 《Current medical research and opinion》2016,32(4):741-747
Background Second targeted therapies for metastatic renal cell carcinoma (mRCC) include mammalian target of rapamycin inhibitors (mTORis) and tyrosine kinase inhibitors (TKIs). This observational study compares overall survival (OS) and progression-free survival (PFS) of patients treated with everolimus (an mTORi) and axitinib (a TKI) following first TKI, and assesses the impact of type and duration of first TKI on the relative effectiveness of these second targeted therapies.Methods Retrospective reviews of medical records were conducted by medical oncologists or hematologists/oncologists recruited from a nationwide panel. Included patients with mRCC were required to have discontinued a first TKI (sunitinib, sorafenib, or pazopanib) for medical reasons, and to have initiated everolimus or axitinib as second targeted therapy between February 2012 and January 2013. OS and PFS were compared between patients treated with everolimus vs. axitinib using multivariable Cox proportional hazards regression models. Comparative results were also stratified by type and duration of first TKI.Results Included patients (n?=?325 for everolimus and n?=?127 for axitinib) had a mean age of 61 years and 31% were female. Sunitinib was the most commonly used first TKI (73%). After adjusting for patient characteristics, no statistically significant differences were observed in OS or PFS between everolimus and axitinib. When stratifying by type and duration of first TKI, there was no statistically significant difference in OS between everolimus and axitinib in all subgroups except for patients with?<6 months on sunitinib or sorafenib as first TKI. No significant difference in PFS was observed in any subgroup.Limitations Important limitations include potential missing or inaccurate data in medical charts, and confounding due to unobserved factors.Conclusions In this retrospective chart review, no significant differences were detected in OS or PFS between axitinib and everolimus as second targeted therapy. Longer duration of first TKI was not associated with increased effectiveness of subsequent axitinib compared to everolimus. 相似文献
14.
15.
16.
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience 总被引:2,自引:0,他引:2
Artz AS Van Besien K Zimmerman T Gajewski TF Rini BI Hu HS Stadler WM Vogelzang NJ 《Bone marrow transplantation》2005,35(3):253-260
Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there are limited long-term follow-up data. Between February 1999 and May 2003, 18 patients with metastatic RCC underwent 19 matched-sibling NSTs after conditioning with fludarabine and cyclophosphamide with tacrolimus and mycophenolate mofetil as post-transplant immunosuppression. Among the four objective responses, all were partial and have relapsed with a median response duration of 609 days (range, 107-926). All responders are alive at a median of 41 months. Median overall survival for the entire cohort was 14 months. There were four early treatment-related deaths and one late treatment-related death. Eight patients died from progressive disease and five (28%) from treatment-related mortality. Stratifying transplant outcome as early death, intermediate (no response, no early death), or response, the combination of pre-treatment anemia and decreased performance status, was associated with adverse outcome (P = 0.015) and reduced survival (HR 5.4, 95% confidence interval of 1.4 to 21, P = 0.007). Responders demonstrated prolonged survival compared to nonresponders (P = 0.002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification. 相似文献
17.
18.
S Desai T Diener BJ-K Tan NJ Lowry C Talukdar WM Chrusch S Wiebe 《The Canadian Journal of Infectious Diseases & Medical Microbiology》2014,25(4):227-228
The present article reports a case involving an immunocompetent, previously well child who, despite two previous doses of inactivated poliovirus vaccine, developed severe flaccid paralysis consistent with polio after receiving oral polio vaccine. 相似文献
19.
Boelens MC van den Berg A Vogelzang I Wesseling J Postma DS Timens W Groen HJ 《Journal of clinical pathology》2007,60(6):608-614
BACKGROUND: Changes in epithelial cell interactions have been implicated in carcinogenesis, tumour invasion and metastasis. AIM: To screen for altered expression of epithelial adhesion genes in lung cancer development. METHODS: Gene expression profiles were assessed with cDNA expression arrays in eight non-small cell lung cancer (NSCLC) and eight normal bronchi obtained from the same patient. Immunohistochemistry (IHC) and RNA in situ hybridisation (ISH) were used to confirm the most prominently expressed adhesion molecules and to investigate their distribution at protein and mRNA levels. RESULTS: 43 differentially expressed cancer-related genes were identified in adenocarcinoma, squamous cell carcinoma (SCC) and normal bronchus. Five of these genes are related to epithelial adhesion-that is, integrin alpha3 (ITGA3), integrin beta4 (ITGB4), desmoplakin I and II (DSP), plakoglobin, and desmocollin 3 (DSC3). ITGA3 and ITGB4, showing predominantly cell-matrix staining, were up regulated in adenocarcinoma and SCC, respectively. ITGB4 also showed strong staining in SCC with IHC and ISH. Components of the desmosome adhesion complex DSP, plakoglobin and DSC3 were strongly up regulated in SCC and showed a distinct cell-cell staining pattern. DSP and plakoglobin were predominantly present at central, more differentiated tumour cells, whereas DSC3 showed a stronger staining in the peripheral basal cells of SCC tumour areas. CONCLUSIONS: Lack of cellular adhesion may have an important role in the metastatic potency of a primary tumour. A possible association of strong presence and normal-distributed desmosomal molecules in SCC with the less frequent and late pattern of metastasis in SCC as compared with adenocarcinoma is suggested. 相似文献
20.